We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Diagnosis of Ovarian Cystic Granulosa Cell Tumors Investigated

By LabMedica International staff writers
Posted on 07 Dec 2022
Print article
Image: Histopathology of Granulosa Cell Tumor of the Ovary: the microfollicular pattern was present focally (Photo courtesy of Dr. Edward Uthman MD)
Image: Histopathology of Granulosa Cell Tumor of the Ovary: the microfollicular pattern was present focally (Photo courtesy of Dr. Edward Uthman MD)

Granulosa cell tumors (GCTs) of both juvenile (JGCT) and adult (AGCT) types may sometimes be completely or predominantly cystic. Interest in this subset of neoplasms has largely been related to their higher frequency of association with androgenic manifestations compared with their typical counterparts.

There is the tendency for cystic tumors to account for a disproportionate number of androgenic GCTs. However, most of the issues associated with these tumors from the perspective of the pathologist relate to their differential diagnosis with a variety of other cystic lesions. The challenge is often significant, in part because of overlapping gross features, but also because of frequent denudation or flattening of the lining epithelium that may impart a non-diagnostic appearance in many areas.

Pathologists at the Massachusetts General Hospital (Boston, MA, USA) and their international colleagues identified 80 cystic GCTs were from their consultation files and the archives of their institution between 1960 and 2020, including eight reported in a prior study. Tumors were included in this study only when the cyst lining was smooth or, at most, slightly granular; tumors with any intracystic solid component were excluded. From two to 28 (average, eight) hematoxylin and eosin–stained slides of tumor were available for review.

Five AGCTs with available material underwent FOXL2 mutation analysis. DNA extractions were performed with a Maxwell RSC DNA FFPE kit on a Maxwell RSC device (Promega, Madison, WI, USA). DNA was quantified using Promega QuantiFluor ONE dsDNA System. Sequencing reactions were carried out on the ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).

The scientists reported that the great majority of the cyst linings in the 24 AGCTs had areas of denudation ranging from minimal to moderate to extensive (>90% denudation in seven). All tumors were greater than 8 cm (average, 17 cm) with minimal to absent gross solid component. Denudation of cells lining the cysts was prominent. Invagination of the epithelium into the cyst walls was a key diagnostic feature, was present as cords, trabeculae, solid nests, and small and large follicles, and was identified in most tumors (17 AGCTs and 45 JGCTs). Cytologic atypia was essentially absent in AGCTs, whereas 14 JGCTs showed moderate to severe atypia of bizarre type. A theca cell component was present in all tumors and was extensive in 54. A FOXL2 hotspot mutation was identified in 1/4 AGCTs tested.

The authors concluded that despite extensive denudation, the finding of typical architectural patterns and cytologic features as well as, in some cases, androgenic manifestations helps differentiate cystic GCTs from follicle cysts, the most common and challenging differential diagnosis, as well as other cystic neoplasms that may enter the differential diagnosis. FOXL2 sequencing may show a false-negative result in cystic AGCT because of the limited number of cells present within the tumor sample. The study was published in the December 2022 issue of the journal Archives of Pathology & Laboratory Medicine.

Related Links:
Massachusetts General Hospital
Promega
Applied Biosystems

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more